Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

77.84 +0.86 (+1.12%)
Official Closing Price Updated: 7:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
From $10k to $100k: 3 Stocks With the Potential for Amazing Returns
Generate massive returns on investment with these three stocks to buy that have the potential to become market beaters in 2024 and beyond. 
Via InvestorPlace
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital... 
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
This messenger-RNA pioneer should be able to keep its rebound going. 
Via The Motley Fool
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Comparative Study: Merck &amp; Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga
3 Reasons to Buy Moderna Stock
The biotech hasn't said its last word. 
Via The Motley Fool
2 Dividend Stocks Billionaires Are Buying: Should You?
That's not a bad crowd to follow when investing in stocks. 
Via The Motley Fool
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside 
Via InvestorPlace
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3... 
Via Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
Via ACCESSWIRE
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly... 
Via Benzinga
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal. 
Via Investor's Business Daily
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
Merck to Acquire EyeBio
From Merck & Co., Inc.
Via Business Wire
No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse. 
Via InvestorPlace
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence
Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing... 
Via Benzinga
Merck Announces Third-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study
Merck's KEYNOTE-522 trial shows Keytruda combined with chemotherapy significantly improves overall survival in high-risk early-stage triple-negative breast cancer patients compared to chemotherapy... 
Via Benzinga
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
For those who appreciate value investing, MERCK & CO. INC. (NYSE:MRK) is a compelling option with its solid fundamentals. 
Via Chartmill
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
Via Benzinga
S&P 500 Plays And One Dow Jones Giant Lead Five Stocks Near Buy Points
These five names are showing relative strength. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.